The protein-based vaccine shows significant promise in preventing rheumatoid arthritis and improving bone quality, suggesting long-term benefits following immunization.
An experimental vaccine developed by researchers at The University of Toledo showed promising results in preventing rheumatoid arthritis, a painful autoimmune disease that cannot currently be cured. The findings are detailed in a paper published in the journal Proceedings of the National Academy of Sciences that generally represent the breakthroughs in the study of rheumatoid arthritis and autoimmune diseases.
‘A vaccine-based strategy targeting a protein can prevent rheumatoid arthritis with maximum benefits.’
Rheumatoid arthritis is one of the most common autoimmune diseases that occurs when the body’s immune system attacks and breaks down the tissue present in the lining of joints in the hands, wrists, ankles, and knees.Some estimates suggest rheumatoid arthritis affects as much as 1% of the global population.
“Despite its high prevalence, there is no cure and we don’t entirely know what brings it on. This is true of nearly all autoimmune diseases, which makes treating or preventing them so difficult,” said Dr. Ritu Chakravarti, an assistant professor in the UToledo College of Medicine and Life Sciences and the paper’s lead author.
Researchers focused on a protein called 14-3-3 zeta, which they considered as a potential trigger for rheumatoid arthritis based on their previous work.
During this research, they discovered that removing that protein through gene-editing technology caused severe early-onset arthritis in animal models.
Advertisement
In addition to suppressing the development of arthritis, the vaccine also significantly improved bone quality, a finding that suggests there should be long-term benefits following immunization.
Advertisement
While those therapeutics can alleviate pain and slow the progression of the disease, they also can make patients more vulnerable to infection and can be costly.
Researchers have filed for a patent on their discovery and are seeking pharmaceutical industry partners to support safety and toxicity studies in hopes of establishing a preclinical trial.
Source-Medindia